Pluri (PLUR) Stock Price

Pluri Price

NASDAQ·CLOSED
0.95
​
Market closed

Revenue has compounded at 2.5% per year over the past 14 years to 1.02 M USD. Pluri's net margin stands at -2,344.6%, up from -17,624.8% several years earlier.

Pluri stock price

Access this data via the Eulerpool API

Pluri business model & stock analysis

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Frequently asked questions about Pluri

7 analysts currently rate the Pluri stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Pluri share trades at 0.85 EUR (0.95 USD).

The Pluri share (PLUR) is listed on 4 stock exchanges, including: NASDAQ (PLUR), Frankfurt (Y55.F), München (Y55.MU).

The revenue of Pluri is 1.02 M USD. This figure is based on current financial data and reflects the company's business performance.

The profit of Pluri is -23.82 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pluri is currently -0.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pluri stock.

The price-to-sales ratio (P/S) of Pluri is currently 10.12. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pluri stock.

The Eulerpool Quality Score for Pluri is 3/10.

The ISIN of Pluri is US72942G2030. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pluri is A3DQ8D. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pluri is PLUR. The ticker symbol is used to trade Pluri shares on the stock exchange.

Fair ValueTerminal
0.81 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
8,260.16 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Israel
Currency
USD
Initial public offering
Dec 10, 2007
ISIN
US72942G2030
Cusip
72942G104
Market capitalization
9.55 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-0.54
P/Se
1.01
EV/EBIT
—
P/B Ratio
99.45
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-200.55 %
Last updated Oct 10, 2026, 8:51 PM

Pluri Peer Group

Pluri Ticker

FRANKFURT · Y55.FMUNICH · Y55.MUNASDAQ · PLURTLV · PLUR.TA

All fundamentals and in-depth analysis of Pluri

Our stock analysis for Pluri stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pluri. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.